Flexion Therapeutics

Flexion Therapeutics focuses on development and commercialization of non-opioid pain therapies. Read more

622 Followers on Owler
622 Followers on Owler
622 Followers on Owler
622 Followers on Owler

Flexion Therapeutics

Flexion Therapeutics focuses on development and commercialization of non-opioid pain therapies. Read more

Mike Clayman's photo - Co-Founder & CEO of Flexion Therapeutics

Co-Founder & CEO

Mike Clayman

CEO Approval Rating

74/100

Founded:

2007

Status:

PublicIndependent CompanyNASDAQFLXN

FLEXION THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Spinifex Pharmaceuticals Pty. Ltd. is perceived as one of Flexion Therapeutics's biggest rivals. Spinifex Pharmaceuticals Pty. Ltd. was founded in 2005, and its headquarters is in Preston, Victoria. Spinifex Pharmaceuticals Pty. Ltd. competes in the field. Spinifex Pharmaceuticals Pty. Ltd. has 242 fewer employees than Flexion Therapeutics.

Calmar Pain Relief is one of Flexion Therapeutics's top rivals. Calmar Pain Relief is a Private company that was founded in 2009 in West Warwick, Rhode Island. Calmar Pain Relief operates in the industry. Compared to Flexion Therapeutics, Calmar Pain Relief has 252 fewer employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Collegium Pharmaceutical a competitor of Flexion Therapeutics?

Flexion Therapeutics Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$85.6M

Flexion Therapeutics's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 2.1B. Over the last four quarters, Flexion Therapeutics's revenue has grown by 59.1%. Specifically, in Q1 2021's revenue was $24.6M; in Q4 2020, it was $26.3M; in Q3 2020, it was $23.7M; in Q2 2020, Flexion Therapeutics's revenue was $15.5M.

Flexion Therapeutics Acquisitions

No recent acquisitions found related to Flexion Therapeutics

Flexion Therapeutics Funding History

Since Flexion Therapeutics was founded in 2007, it has participated in 5 rounds of funding. In total Flexion Therapeutics has raised $190.0M. Flexion Therapeutics' last funding round was on Aug 2015 for a total of $30.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Aug 2015
$30M
IPO
Feb 2014
$65M

Series B
Dec 2012
$20M
Series A
Jan 2010
$42M
Series A
Sep 2009
$33M

Versant Ventures

Since Flexion Therapeutics was founded in 2007, it has participated in 5 rounds of funding. In total Flexion Therapeutics has raised $190.0M. Flexion Therapeutics' last funding round was on Aug 2015 for a total of $30.0M

Flexion Therapeutics Investments

No recent investments found related to Flexion Therapeutics

Flexion Therapeutics News

April 13, 2021BioSpace

Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonid... See more »
April 13, 2021MarketScreener

Q1 2021 Commercial Metrics Overview

(marketscreener.com) Q1 2021 Commercial Metrics April 13, 2021 Commercial Metrics Overview • • ...htt... See more »
April 2, 2021BioSpace

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 02, 2021

Flexion Therapeutics, Inc. announced equity inducement grants to five new employees consisting of 60,... See more »
March 10, 2021BioSpace

Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results

Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales... See more »
March 5, 2021BioSpace

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 05, 2021

Flexion Therapeutics, Inc. announced equity inducement grants to four new employees consisting of 14,... See more »

Flexion Therapeutics Press Releases

March 15, 2021GlobeNewswire

Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference

BURLINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announ... See more »
March 5, 2021GlobalNewswire

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today ... See more »
March 1, 2021StreetInsider

Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain

FX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate ... See more »
February 22, 2021GlobeNewswire

Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference

BURLINGTON, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announc... See more »
February 18, 2021StreetInsider

Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups

First-in-human single ascending dose trial advances to high dose cohort following positive Data Monit... See more »
May 13, 2020GlobeNewswire

Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference

BURLINGTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announce... See more »
May 7, 2020GlobeNewswire

Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights

BURLINGTON, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today re... See more »

Social Media

Flexion Therapeutics Headquarters

10 Mall Road Suite 301

Burlington, Massachusetts01803

781-305-7777

Driving Directions »

Trending Companies

Flexion Therapeutics Summary

ABOUT

Overview

Flexion Therapeutics focuses on development and commercialization of non-opioid pain therapies. Flexion Therapeutics was founded in 2007. Flexion Therapeutics' headquarters is located in Burlington, Massachusetts, USA 01803. It has raised 190.0M in 5 ...

CEO

Flexion Therapeutics's Co-Founder & CEO, Mike Clayman, currently has an approval rating of 74%. Flexion Therapeutics's primary competitors are Spinifex Pharmaceuticals Pty. Ltd., Calmar Pain Relief & Calmare.

Website

flexiontherapeutics.com

Frequently Asked Questions about Flexion Therapeutics

  1. When was Flexion Therapeutics founded?

    Flexion Therapeutics was founded in 2007
  2. Who is Flexion Therapeutics's CEO?

    Flexion Therapeutics's CEO is Mike Clayman
  3. How much revenue does Flexion Therapeutics generate?

    Flexion Therapeutics generates $85.6M in revenue
  4. How much funding does Flexion Therapeutics have?

    Flexion Therapeutics has historically raised $190M in funding
  1. Where is Flexion Therapeutics's headquarters?

    Flexion Therapeutics's headquarters is in Burlington Massachusetts, USA
  2. How many employees does Flexion Therapeutics have?

    Flexion Therapeutics has 272 employees
  3. What sector does Flexion Therapeutics operate in?

    Flexion Therapeutics is in Pharmaceuticals, Biotechnology
  4. Who are Flexion Therapeutics's competitors?

    Flexion Therapeutics's top competitors are Spinifex Pharmaceuticals Pty. Ltd., Calmar Pain Relief, Calmare